Recombinant Human PEA15

Description

EnkiLife provides the Recombinant Human PEA15 protein,aslo know as Astrocytic Phosphoprotein PEA-15,15 kDa Phosphoprotein Enriched in Astrocytes,Phosphoprotein Enriched in Diabetes,PED,PEA15, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human Phosphoprotein Enriched in Astrocytes of 15 kDa is produced by our E.coli expression system and the target gene encoding Met1-Ala130 is expressed.Accession:Q15121. Expression Host:E.coli.Species:Human.Predicted Molecular Mass:15.3 KDa. Background:Astrocyticphosphoprotein PEA-15 (PEA15) is a death effector domain (DED)-containing protein. PEA15 is mainly expressed in the central nervous system, principally in astrocytes. Increased PEA15 levels affect tumorigenesis and cancer progression. PEA15 is overexpressed in breast cancers and gliomas as well as in type 2 diabetes. PEA15 blocks Ras-mediated inhibition of integrin activation and modulates the ERK MAP kinase cascade. PEA15 also inhibits RPS6KA3 activities by holding it in the cytoplasm. In addition, PEA15 inhibits both TNFRSF6 and TNFRSF1A mediated CASP8 activity and apoptosis. At present, PEA15 expression is also a significant prognostic marker in ovarian cancer.